Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Maven Clinic vs Medro

Maven Clinic
Graded #383

Lower grade

vs+5.600000000000001
Medro
Graded #256

Higher grade

The verdict

Medro takes it — 63.6/100 to 58/100.

Medro grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Medro (Medro Health Technologies, Inc.) is a telehealth brand whose GLP-1 program offers compounded semaglutide and tirzepatide, plus brand-name GLP-1s when eligible, via a partner medical group and…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMedro +5
45
50
Dose & formulationMedro +24
53
77
Clinical oversightMaven Clinic +6
77
71
Labs & monitoringMaven Clinic +1
53
52
FulfillmentMedro +22
70
92
Contract termsMaven Clinic +22
55
33
Maven Clinic · left barMedro · right bar

The numbers

MetricMaven ClinicMedro
WeighScore58/10063.6/100
GradeCC
Scorecard rank#383#256
SemaglutideNot disclosed$199/mo (compounded)
TirzepatideNot disclosed$299/mo (compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
Maven Clinic

Graded #383 · C

Strengths

  • Dedicated GLP-1 Care program with brand-name (FDA-approved) GLP-1 prescriptions
  • On-demand visits with metabolic and hormone-health specialists, plus nutrition and strength support
  • Integrated with broader women's, hormone, and family health care
  • LegitScript-verified; trusted by 2,300+ employers
  • Available as both an employer health benefit and a consumer self-pay option

Where it loses points

  • Pricing is not published on the public site
  • Primarily distributed through employers and health plans — direct access can depend on your plan
  • US state availability for GLP-1 is not specified publicly
  • Brand-name only — no lower-cost compounded option
Medro

Graded #256 · C

Strengths

  • Covers both compounded semaglutide and tirzepatide and can prescribe brand-name GLP-1s when clinically appropriate.
  • LegitScript-certified (seal #50716646), available in all 50 states, with tiered pricing shown before checkout.
  • No membership fee and free expedited shipping on all orders; online intake with no appointment required in many cases.
  • Prices drop with longer commitments (semaglutide to $149/mo, tirzepatide to $224/mo on a 12-month plan).

Where it loses points

  • Does not name its compounding pharmacy or its clinical partner medical group, so the fulfillment chain is not verifiable.
  • Pricing is described as illustrative and may change by dose, pharmacy availability, and eligibility — final cost shows only at checkout.
  • Very new brand (2026, trademark pending) spanning many verticals, with a short track record in GLP-1 care.
  • Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard